The effect of eplerenone on all-cause mortality and heart failure hospitalization in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS)

Abstract

Purpose: In EPHESUS, eplerenone (EPL) significantly decreased the risk of hospitalization for heart failure (HF) versus placebo (PBO) when added to standard HF treatment in patients with left ventricular dysfunction (LVD) and signs of HF after acute myocardial infarction (AMI). Because HF hospitalization is a major morbid event for HF patients, we retrospectively evaluated the effect of EPL added to standard HF treatment on the composite endpoint of time to all-cause mortality or HF hospitalization in high-risk subgroups and determined the risk of death in patients hospitalized for HF.